← Back to Search

MRI Brain and Cervical Spine for Multiple Sclerosis

Phase < 1
Waitlist Available
Led By M. Mateo Paz Soldan, MD, PhD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinically diagnosed with secondary progressive multiple sclerosis (SPMS) (2017 McDonald Criteria)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 96 hours ±24 hours
Awards & highlights

Study Summary

This trial uses USPIO nanoparticles and MRI to measure activity in the innate immune system within MS lesions, in order to find a biomarker for chronic-active lesions.

Eligible Conditions
  • Secondary Progressive Multiple Sclerosis
  • Multiple Sclerosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with a specific type of multiple sclerosis called secondary progressive multiple sclerosis (SPMS) based on certain criteria.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~96 hours ±24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 96 hours ±24 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Signal change on T1-weighted and 3D UTE MRI brain (and upper cervical cord) before and 96 hours (±24 hours) after ferumoxytol administration
Secondary outcome measures
Incidence of treatment-emergent adverse events (safety and tolerability)

Trial Design

1Treatment groups
Experimental Treatment
Group I: SPMS CohortExperimental Treatment3 Interventions
Subjects will undergo MR imaging of the brain and cervical spine for pre- and post-administration of gadoteridol (0.2 mL/kg), then pre- and post-administration of ferumoxytol (4 mg/kg). Scans will be obtained over the course of two separate imaging visits.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ferumoxytol infusion
2021
Completed Early Phase 1
~20
Gadoteridol
2015
Completed Early Phase 1
~40
MRI Brain and Cervical Spine
2022
Completed Early Phase 1
~20

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,088 Previous Clinical Trials
1,728,338 Total Patients Enrolled
3 Trials studying Multiple Sclerosis
213 Patients Enrolled for Multiple Sclerosis
M. Mateo Paz Soldan, MD, PhDPrincipal InvestigatorUniversity of Utah

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being recruited into this investigation?

"Indeed, as per clinicaltrials.gov's listing, this research initiative is currently searching for volunteers. The trial was first published on June 1st 2022 and was recently updated on June 22nd 2022. Its goal is to find 10 individuals from one location."

Answered by AI

Does this investigation have an age cap for participation?

"Participants must be within the age range of 35 - 65 in order to meet this trial's enrollment requirements."

Answered by AI

Am I eligible to be a part of this research endeavor?

"Applicants must suffer from multiple sclerosis and be between the ages of 35-65 to qualify for this medical trial. The total number of participants is capped at 10 individuals."

Answered by AI

Are there any openings still available to participate in this research?

"Affirmative. Clinicaltrials.gov indicates that this medical trial is presently seeking participants, having been first posted on June 1st 2022 and recently edited on the 22nd of the same month. The research requires 10 people to be enrolled at one site."

Answered by AI
~4 spots leftby Mar 2025